Ligand Pharmaceuticals (LGND) Net Cash Flow Growth (1y) (2011 - 2026)
Ligand Pharmaceuticals (LGND) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-14,223.53% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Ligand Pharmaceuticals |
5.47 Bn |
4.69 Bn |
48.45 Mn |
-136.34% |
| Date | Value |
|---|
| Mar 31, 2026 |
-136.34% |
| Dec 31, 2025 |
253.08% |
| Sep 30, 2025 |
53.63% |
| Jun 30, 2025 |
162.99% |
| Mar 31, 2025 |
-193.22% |
| Dec 31, 2024 |
230.62% |
| Sep 30, 2024 |
625.25% |
| Jun 30, 2024 |
46.99% |
| Mar 31, 2024 |
-37.93% |
| Dec 31, 2023 |
-92.43% |
| Sep 30, 2023 |
-637.71% |
| Jun 30, 2023 |
-520.64% |
| Mar 31, 2023 |
1,065.38% |
| Dec 31, 2022 |
1,146.58% |
| Sep 30, 2022 |
-181.80% |
| Jun 30, 2022 |
4.68% |
| Mar 31, 2022 |
71.27% |
| Dec 31, 2021 |
99.05% |
| Sep 30, 2021 |
-99.58% |
| Jun 30, 2021 |
-328.15% |
